AlloVir Yönetim

Yönetim kriter kontrolleri 4/4

AlloVir CEO'su Vikas Sinha, Jan2019 tarihinde atandı, in görev süresi 6.17 yıldır. in toplam yıllık tazminatı $ 544.40K olup, şirket hissesi ve opsiyonları dahil olmak üzere 69% maaş ve 31% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.87% ine doğrudan sahiptir ve bu hisseler $ 419.01K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.2 yıl ve 3.8 yıldır.

Anahtar bilgiler

Vikas Sinha

İcra Kurulu Başkanı

US$544.4k

Toplam tazminat

CEO maaş yüzdesi	69.0%
CEO görev süresi	6.2yrs
CEO sahipliği	0.9%
Yönetim ortalama görev süresi	6.2yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04

AlloVir EPS misses by $0.28

Nov 10

CEO Tazminat Analizi

Vikas Sinha'un ücretlendirmesi AlloVir'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2024	US$544k	US$375k	-US$59m
Sep 30 2024	n/a	n/a	-US$100m
Jun 30 2024	n/a	n/a	-US$140m
Mar 31 2024	n/a	n/a	-US$180m
Dec 31 2023	US$3m	US$373k	-US$190m
Sep 30 2023	n/a	n/a	-US$169m
Jun 30 2023	n/a	n/a	-US$167m
Mar 31 2023	n/a	n/a	-US$166m
Dec 31 2022	US$3m	US$369k	-US$169m
Sep 30 2022	n/a	n/a	-US$189m
Jun 30 2022	n/a	n/a	-US$192m
Mar 31 2022	n/a	n/a	-US$185m
Dec 31 2021	US$7m	US$425k	-US$172m
Sep 30 2021	n/a	n/a	-US$139m
Jun 30 2021	n/a	n/a	-US$117m
Mar 31 2021	n/a	n/a	-US$91m
Dec 31 2020	US$6m	US$412k	-US$70m
Sep 30 2020	n/a	n/a	-US$53m
Jun 30 2020	n/a	n/a	-US$37m
Mar 31 2020	n/a	n/a	-US$31m
Dec 31 2019	US$2m	US$400k	-US$24m

Tazminat ve Piyasa: Vikas 'ın toplam tazminatı ($USD 544.40K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 641.60K ).

Tazminat ve Kazançlar: Vikas 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Vikas Sinha (61 yo)

6.2yrs

Görev süresi

US$544,400

Tazminat

Mr. Vikas Sinha, M.B.A., C.A., CPA, is Director of Orna Therapeutics, Inc. from January 2025. Mr. Sinha is CEO of AlloVir, Inc. from December 19, 2024 and has been its Director since January 2019 and serve...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Hallal	Executive Chairman of the Board	6.5yrs	US$227.03k	2.46% $ 1.2m
Vikas Sinha	CEO, President	6.2yrs	US$544.40k	0.87% $ 419.0k
Brett Hagen	Chief Accounting Officer	6.2yrs	US$796.31k	0.018% $ 8.8k
Edward Miller	General Counsel & Secretary	6.2yrs	US$645.69k	0.38% $ 184.4k
Ann Leen	Chief Scientific Officer	12.2yrs	Veri yok	Veri yok

6.2yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: ALVR 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Hallal	Executive Chairman of the Board	6.5yrs	US$227.03k	2.46% $ 1.2m
Vikas Sinha	CEO, President	6.2yrs	US$544.40k	0.87% $ 419.0k
John Mellors	Member of the Scientific Advisory Board	2.1yrs	Veri yok	Veri yok
Malcolm Brenner	Independent Non-Executive Director	13.2yrs	US$77.03k	0.20% $ 96.3k
Jeffrey Bornstein	Independent Non-Executive Director	4.7yrs	US$94.53k	0.066% $ 31.6k
Michael Boeckh	Member of Scientific Advisory Board	2.1yrs	Veri yok	Veri yok
John DiPersio	Member of Scientific Advisory Board	2.1yrs	Veri yok	Veri yok
Anil Chandraker	Member of Scientific Advisory Board	2.1yrs	Veri yok	Veri yok
Morana Jovan-Embiricos	Independent Non-Executive Director	5.8yrs	US$92.03k	8.64% $ 4.2m
Shawn Tomasello	Independent Director	3yrs	US$82.03k	0.031% $ 14.7k
Juan Vera	Non-Executive Director	11.2yrs	US$67.03k	2.08% $ 998.5k
Gerard Socie	Member of Scientific Advisory Board	2.1yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

59.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALVR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/03/13 08:12
Gün Sonu Hisse Fiyatı	2025/03/13 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

AlloVir, Inc. 3 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jason Zemansky	BofA Global Research
Anupam Rama	J.P. Morgan
Christopher Raymond	Piper Sandler Companies

AlloVir Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

High number of new directors

CEO & Director notifies of intention to sell stock

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

Recent updates

New major risk - Market cap size

New major risk - Revenue and earnings growth

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

New minor risk - Share price stability

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Price target decreased by 20% to US$0.80

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

New major risk - Financial position

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Levi & Korsinsky, LLP Notifies Investors in Allovir, Inc. of a Class Action Securities Lawsuit

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Robbins LLP Announces Class Action File Against AlloVir, Inc

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Price target decreased by 71% to US$5.63

AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

New major risk - Share price stability

AlloVir, Inc. Presents Positive Final Results from A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of Bk Infection in Kidney Transplant Recipients At the American Transplant Congress

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

High number of new directors

Price target decreased by 7.6% to US$21.25

AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia

Price target decreased by 13% to US$23.00

CEO & Director notifies of intention to sell stock

AlloVir, Inc. Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

AlloVir, Inc. Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

General Counsel & Secretary notifies of intention to sell stock

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir, Inc. Announces That Final Data from the Phase 2 Study of Posoleuce

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board notifies of intention to sell stock

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board recently sold US$2.9m worth of stock

Chief Commercial Officer recently sold US$129k worth of stock

Price target decreased to US$27.50

AlloVir GAAP EPS of $0.69 beats by $1.42

AlloVir stock surges on $126.6M securities offering

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

AlloVir, Inc.(NasdaqGS:ALVR) dropped from Russell 2000 Growth Index

AlloVir, Inc. Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

Chief Commercial Officer recently sold US$67k worth of stock

Price target decreased to US$32.00

FDA Grants Regenerative Medicine Advanced Therapy to Allovir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

AlloVir, Inc., Annual General Meeting, May 17, 2022

AlloVir Announces Appointment of Shawn Tomasello to its Board of Directors

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Chief Commercial Officer recently sold US$128k worth of stock

AlloVir: A Comparative Study Of Its Manufacturing Process

Price target decreased to US$38.75

Insider notifies of intention to sell stock

President recently sold US$56k worth of stock

AlloVir, Inc. Announces U.S. Food and Drug Administration Grant Lead Multi-Virus Specific T Cell (VST) Therapy, Posoleucel (Viralym-M, ALVR105), Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Adenovirus (AdV) Infection

Price target decreased to US$42.75

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting

Chief Commercial Officer recently sold US$321k worth of stock

Chief Scientific Officer notifies of intention to sell stock

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

High number of new directors

Independent Non-Executive Director notifies of intention to sell stock

Insider recently sold US$447k worth of stock

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Insider notifies of intention to sell stock